



FASENRA (benralizumab)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

<u>Part A – Patient</u> Patient Information

Fatient information					
First Name:			Last Name:		
Insurance Carrier N	lame/Number:				
Group Number:			Client ID:		
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent		
Language: English French			Gender: Male Female		
Address:					
City:		Province:		Postal Code:	
Email address:					
Telephone (home):		Telephone (cell):		Telephone (work):	
Please check any box that applies to the patient: The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed. The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.					
Coordination of benefits					
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.				
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A What is the coverage decision of the drug? Approved Denied *Attach decision letter*				





FASENRA (benralizumab)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





FASENRA (benralizumab)

Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

FASENRA (benralizumab)		☐ New request ☐ Renewal request*		
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
	on:			
Home Physi	cian's office/Private Clir	nic Private Clinic (within Hos	spital - no public or go	overnment funding)
Hospital (inpatient)	Hospital (outpat	tient)		
Name of the hospital or		,		
rame of the noopital of	private omno.			
Address:				
City:	Pro	vince:	Postal code:	
	of prior coverage if avai	lahla		
* Please submit proof	or prior coverage ir avai	lable		
·		lable		
ECTION 2 – ELIGIBI	LITY CRITERIA			
SECTION 2 – ELIGIBI				
SECTION 2 – ELIGIBI 1. Please indicate if the	LITY CRITERIA ne patient satisfies the b			
SECTION 2 – ELIGIBI 1. Please indicate if the	LITY CRITERIA ne patient satisfies the b			
1. Please indicate if the Severe Eosinophilic Ast	LITY CRITERIA ne patient satisfies the b		n adult, AND	
1. Please indicate if the Severe Eosinophilic Ast INITIAL For the add-on The patient is in	LITY CRITERIA ne patient satisfies the b hma maintenance treatment	pelow criteria: t of severe eosinophilic asthma in arwith high-dose inhaled corticosteroic		ditional asthma
1. Please indicate if the Severe Eosinophilic Ast INITIAL For the add-on The patient is in controller(s) (e.	LITY CRITERIA ne patient satisfies the k hma maintenance treatment nadequately controlled to g. long-acting beta agor is had 2 or more asthma	pelow criteria: t of severe eosinophilic asthma in arwith high-dose inhaled corticosteroic	ds, and 1 or more add	
1. Please indicate if the Severe Eosinophilic Ast INITIAL For the add-on The patient is in controller(s) (e. In the patient has 12 months and Interest in the In	LITY CRITERIA ne patient satisfies the k hma maintenance treatment nadequately controlled to g. long-acting beta agor is had 2 or more asthmat has a blood eosinophil is a blood eosinophil cou	pelow criteria: t of severe eosinophilic asthma in arwith high-dose inhaled corticosteroichists), AND exacerbations requiring treatment v	ds, and 1 or more add with systemic corticos R	steroids in the past
1. Please indicate if the Severe Eosinophilic Astronomy For the add-on The patient is in controller(s) (e. The patient has 12 months and The patient has	LITY CRITERIA ne patient satisfies the k hma maintenance treatment nadequately controlled to g. long-acting beta agor is had 2 or more asthmat has a blood eosinophil is a blood eosinophil cou	below criteria: It of severe eosinophilic asthma in an with high-dose inhaled corticosteroichists), AND exacerbations requiring treatment vocunt of 300 cells/µL or greater, OF	ds, and 1 or more add with systemic corticos R	steroids in the past
1. Please indicate if the Severe Eosinophilic Ast INITIAL For the add-on The patient is in controller(s) (e. The patient has 12 months and	LITY CRITERIA ne patient satisfies the k hma maintenance treatment nadequately controlled to g. long-acting beta agor is had 2 or more asthmat has a blood eosinophil is a blood eosinophil cou	below criteria: It of severe eosinophilic asthma in an with high-dose inhaled corticosteroichists), AND exacerbations requiring treatment vocunt of 300 cells/µL or greater, OF	ds, and 1 or more add with systemic corticos R	steroids in the past
1. Please indicate if the Severe Eosinophilic Ast INITIAL For the add-on The patient is in controller(s) (e. The patient has 12 months and The patient has corticosteroids RENEWAL	LITY CRITERIA ne patient satisfies the behavior of the patient satisfies a blood evaluation of the patient satisfies a blood evaluation of the patient satisfies the behavior of the patient satisfies the patient satisfies the behavior of the patient satisfies the patient satisfies the behavior of the patient satisfies the patient	below criteria: It of severe eosinophilic asthma in an with high-dose inhaled corticosteroichists), AND exacerbations requiring treatment vocunt of 300 cells/µL or greater, OF	ds, and 1 or more add with systemic corticos R eceiving maintenance	steroids in the past e treatment with ora





FASENRA (benralizumab)

OR None of the above criteria applies.			
Relevant additional information:			
SECTION 3 – PRESCRIBER INFORMATION			
Physician's Name:			
Address:			
Tel:	Fax:		
License No.:	Specialty:		
Physician Signature:	Date:		

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





FASENRA (benralizumab)

SECTION 5 - CONTACT US

	You can submit all pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the reference number.
_	

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept.
PO Box 2010 STN Waterloo
Waterloo, ON N2J 0A6